Skip to main content
Clinical Trials/NCT01294865
NCT01294865UnknownNot Applicable

The Plasma Levels of suPAR in Late-onset Neonatal Sepsis

Ankara University1 site in 1 country120 target enrollmentStarted: January 2010Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
120
Locations
1
Primary Endpoint
Levels of suPAR in late-onset neonatal sepsis

Study Overview

Brief Summary

The purpose of the study is to investigate the plasma levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) at the diagnosis and after treatment of sepsis, and to determine whether it has a diagnostic and prognostic value in late-onset neonatal sepsis.

Detailed Description

Infection is a leading cause of neonatal morbidity and mortality worldwide. The clinical presentation of neonatal infection is subtle and nonspecific. Microbiologic cultures of clinical specimens, the gold standard for diagnosis, have low sensitivity and are not available in time to influence initial therapy. Therefore, reliable and rapid in vitro tests are needed for early diagnosis and management of infection in neonates. suPAR, secreted from the cells (neutrophils, lymphocytes, macrophages, endothelial cells) has recently been reported to be a potential biomarker for several infection diseases. The levels of suPAR have not been studied in newborn infants yet.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
4 Days to 1 Month (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Infants with late-onset neonatal sepsis

Exclusion Criteria

  • Infants without parents' consent

Outcomes

Primary Outcomes

Levels of suPAR in late-onset neonatal sepsis

Time Frame: three weeks

Levels of suPAR will be dosed with suspicion of late-onset sepsis diagnosis at day 0 and at the end of the treatment. The evolution and the best cut-off values will be calculated for the diagnosis. Indices of sensibility, specificity, positive predictive value and negative predictive value will be calculated.

Secondary Outcomes

  • Level of plasma C-reactive protein(three weeks)
  • the white blood cell count(three weeks)

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials